An AAV Gene Therapy Trial of AFTX-201 in Adults With BAG3-Associated Dilated Cardiomyopathy (DCM) (UPBEAT)
A Phase 1/2 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Trial to Assess the Safety, Tolerability, Pharmacodynamics, and Preliminary Efficacy of AFTX-201 Administered to Adult Participants With BCL2-Associated Athanogene 3 (BAG3) Mutation-Associated Dilated Cardiomyopathy: UPBEAT Trial
This is a Phase 1/2, open-label, dose-exploration and dose-expansion, clinical trial evaluating the safety, tolerability, pharmacodynamics, and preliminary efficacy of a single intravenous infusion of AFTX-201 in adults with dilated cardiomyopathy caused by a BAG3 gene mutation
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Participants will receive a single intravenous infusion of AFTX-201 and will be followed for safety and clinical assessments. The study includes short-term safety monitoring and long-term follow-up for up to 60 months
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Clinical Trials Information
- Phone Number: 2 (617) 430-7817
- Email: clinicaltrials@affiniatx.com
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, QC H1T 1C8
- Recruiting
- Institut de Cardiologie de Montréal / Montreal Heart Institute
-
Contact:
- Jérémie Coordonnateur de recherche EPS / EP research coordinator, BScN
- Phone Number: 2293 514-376-3330
- Email: Jeremie.Cortial@icm-mhi.org
-
Principal Investigator:
- Rafik Tadros, MD
-
-
-
-
Florida
-
Miami, Florida, United States, 33136
- Recruiting
- University of Miami Hospital and Clinics
-
Contact:
- Lina Carceres
- Phone Number: 954 249 3587
- Email: caceresl@miami.edu
-
Principal Investigator:
- Joshua Hare, MD
-
-
Missouri
-
Kansas City, Missouri, United States, 64111
- Recruiting
- St. Lukes Hospital
-
Principal Investigator:
- Andrew Kao, MD
-
Contact:
- Amanda Huffman, RN, BSN
- Phone Number: 816-932-0391
- Email: amanda.huffman@bjc.org
-
-
New York
-
New York, New York, United States, 10016
- Recruiting
- NYU Langone
-
Principal Investigator:
- Tajinderpal Saraon, MD
-
Contact:
- Loriya Thao
- Phone Number: 646-877-6343
- Email: loriya.thao@nyulangone.org
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- Houston Methodist Hospital
-
Principal Investigator:
- Cindy Martin, MD
-
Contact:
- Jennifer (Garrett) Medley Sr. Clinical Trials Manager
- Phone Number: 346-238-4516
- Email: jmgarrett@houstonmethodist.org
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Male or female, 18 to 70 years of age
Truncating mutation in BAG3
Dilated cardiomyopathy with left ventricular ejection fraction (LVEF) < 50% by echocardiogram or cardiac MRI
NYHA Class II or III heart failure symptoms
Body weight ≤ 120 kg
Willing and able to sign informed consent and comply with study procedures
Exclusion Criteria:
Prior myocardial infarction when, in the investigator's judgment, the totality of clinical and imaging evidence supports that left ventricular dysfunction is due to coronary artery disease rather than BAG3-associated dilated cardiomyopathy
Prior heart transplant
Presence or requirement of a left ventricular assist device (LVAD)
IV therapy with positive inotropes, vasodilators, or diuretics for heart failure within 30 days prior to enrollment
Positive neutralizing antibodies to ATC-0187
Any condition that, in the investigator's opinion, would place the subject at undue risk or interfere with study participation or interpretation of results
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: AFTX-201
Participants will receive a single intravenous dose of AFTX-201 |
AFTX-201 is a gene therapy product consisting of the ATC-0187 capsid containing the BCL2-associated Athanogene 3 (BAG3) transgene. It is administered as a single intravenous infusion |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
Time Frame: Baseline through 12 months
|
Safety and tolerability of AFTX-201 over 12 months. |
Baseline through 12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline in pharmacodynamic biomarkers
Time Frame: Baseline through 12 months
|
Assessment of the extent of AFTX-201 transduction and myocardial BAG3 protein expression after a single IV dose |
Baseline through 12 months
|
|
Change from baseline in measurement of cardiac function including left ventricular ejection fraction (LVEF)
Time Frame: Baseline through 12 months
|
Assessment of the impact of a single IV dose of AFTX-201 on measurement of cardiovascular function |
Baseline through 12 months
|
|
Change from baseline in measurement of cardiac function including peak oxygen consumption (pVO2) by cardiopulmonary exercise test (CPET)
Time Frame: Baseline through 12 months
|
Assessment of the impact of a single IV dose of AFTX-201 on measurement of cardiovascular function |
Baseline through 12 months
|
|
Change from baseline in New York Heart Association (NYHA) functional class
Time Frame: Baseline through 12 months
|
Assessment of the impact of a single IV dose of AFTX-201 on features of heart failure (HF) including functional classification by New York Heart Association (NYHA) class |
Baseline through 12 months
|
|
Change from baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ)
Time Frame: Baseline through 12 months
|
Assessment of the impact of a single IV dose of AFTX-201 on quality of life |
Baseline through 12 months
|
|
Change from baseline in NT-proBNP levels through 12 months
Time Frame: Baseline through 12 months
|
Assessment of the change from baseline in NT-proBNP levels following a single intravenous dose of AFTX-201 |
Baseline through 12 months
|
|
Change from baseline in NT-proBNP levels during long-term follow-up
Time Frame: Baseline through 60 months
|
Assessment of the change from baseline in NT-proBNP levels during long-term follow-up following a single intravenous dose of AFTX-201 |
Baseline through 60 months
|
|
Number of participants with adverse events during long-term follow-up
Time Frame: Baseline through 60 months
|
Safety and tolerability of AFTX-201 over 60 months |
Baseline through 60 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- AFTX-201-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.